Keywords: solid state; coformer; anti-viral; telaprevir; solubility; crystal engineering; formulation; cocrystal;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: creatinine; MATE1; MATE2-K; OCT2; renal transporter; telaprevir;
Keywords: Hepatitis C; Protease inhibitors; Telaprevir; Dermatitis; Eczema; ToxicodermaHepatitis C; Inhibidores de la proteasa; Telaprevir; Dermatitis; Eccema; Toxicodermia
Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy
Keywords: Hepatitis C; Relapse; Direct-acting antivirals; Neutralizing antibodies; Sustained virological response; E1E2 envelope; HCV; hepatitis C virus; DAA; direct-acting antiviral; SVR; sustained virological response; RBV; ribavirin; PEG-IFN; pegylated-interfero
Simulations of Cytochrome P450 3A4-Mediated Drug-Drug Interactions by Simple Two-Compartment Model-Assisted Static Method
Keywords: bioavailability; cytochrome P450; drug interaction; dynamic simulation; first pass metabolism; hepatic clearance; intestinal metabolism; pharmacokinetics; simulations; parallel tube model; Ae (Ae,oral); dose fractions of urinary excreted unchanged drug af
Pretreatment serum levels of interferon-gamma-inducible protein-10 are associated with virologic response to telaprevir-based therapy
Keywords: Chronic hepatitis C; IL28B; IP-10; Rapid virologic response; Telaprevir; ALT; alanine aminotransferase; AST; aspartate aminotransferase; CHC; chronic hepatitis C; CI; confidential interval; DAA; direct-acting antivirals; ETR; end of treatment virologic re
Research ArticleEfficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials
Keywords: HCV; hepatitis C virus; GT; genotype; TPV; telaprevir; PegIFN; pegylated interferon; RBV; ribavirin; SVR; sustained virologic response; DAA; direct-acting antiviral agents; OBV; ombitasvir; PTV; paritaprevir; r; ritonavir; DSV; dasabuvir; IL28B; interleuk
HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients
Keywords: HIV/HCV-coinfection; HCV undetectable viral load; HCV sustained virologic response; SVR; Telaprevir; Boceprevir; HCV protease inhibitors; Low HCV viral load;
Pharmacokinetic interactions between telaprevir and antiretroviral drugs in HIV/HCV-coinfected patients with advanced liver fibrosis and prior HCV non-responders
Keywords: Telaprevir; Antiretroviral therapy; Pharmacokinetics; Drug interactions;
Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment
Keywords: CNT; concentrative nucleoside transporter; GWAS; genome-wide association studies; Hb; haemoglobin; HCV; hepatitis C virus; ITPA; inosinetriphosphatase; SVR; sustained virological response; Anaemia; Hepatitis C; ITPA; SLC28; Polymorphism; Telaprevir; Bocep
Incidencia, manejo y coste de los efectos adversos hematológicos y dermatológicos durante las 12 primeras semanas de tratamiento con triple terapia para hepatitis C
Keywords: Telaprevir; Boceprevir; Análisis de costes; Hepatitis C crónica; Efectos adversosTelaprevir; Boceprevir; Cost analysis; Chronic hepatitis C; Adverse effects
No correspondence between resistance mutations in the HCV-NS3 protease at baseline and early telaprevir-based triple therapy
Keywords: NS3 protease; HCV; Telaprevir; Drug resistance; Genetic diversity; NGS
The clinical significance of HCV core antigen detection during Telaprevir/Peg-Interferon/Ribavirin therapy in patients with HCV 1 genotype infection
Keywords: Hepatitis C virus; HCVcore antigen; Telaprevir; RVRrapid virological response; EVRearly virological response; SVRsustained virological response;
Toxicodermias por telaprevir en el tratamiento de la infección crónica por el genotipo 1 del virus de la hepatitis C. Estudio prospectivo
Keywords: Telaprevir; Triple terapia; Virus hepatitis C; ToxicodermiaTelaprevir; Triple therapy; Hepatitis C virus; Toxicoderma
Drug Eruptions Induced by Telaprevir in Patients With Chronic Hepatitis C Virus Genotype 1 Infection: A Prospective Study
Keywords: Telaprevir; Triple therapy; Hepatitis C virus; ToxicodermaTelaprevir; Triple terapia; Virus hepatitis C; Toxicodermia
Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients: An early access programme
Keywords: Hepatitis C; Telaprevir; HIV; Coinfection; Cirrhosis; Bridging fibrosis; DAA; direct acting antivirals; HAART; highly active anti-retroviral therapy; HCV; hepatitis C virus; HIV; human immunodeficiency virus; PEG-IFN; peginterferon;
A signature for immune response correlates with HCV treatment outcome in Caucasian subjects
Keywords: Focal adhesion; Response predictor; Direct-acting antiviral; Telaprevir; Proteomic profiling;
UPLC-MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells
Keywords: Tandem-mass; HCV; Intracellular; Boceprevir; Telaprevir; Chromatography;
Telaprevir is a substrate and moderate inhibitor of P-glycoprotein, a strong inductor of ABCG2, but not an activator of PXR in vitro
Keywords: Telaprevir; Drug transporters; CYPs; PXR; Interaction
A case of successful treatment with telaprevir-based triple therapy for hepatitis C infection after treatment failure with vaniprevir-based triple therapy
Keywords: Hepatitis C virus; NS3/4A protease inhibitor; Telaprevir; Vaniprevir; Drug resistance mutation;
A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy
Keywords: Hepatitis C virus; Human immunodeficiency virus; Hemophilia; Antiretroviral therapy; Telaprevir; Pegylated interferon α
Liver, pancreas and biliary tractDefer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents
Keywords: Boceprevir; Chronic hepatitis C genotype 1; DAAs; Telaprevir; Therapy decision; Real-life data;
Anti-interferon-α neutralizing antibody induced telaprevir resistance under the interferon-α plus telaprevir treatment in vitro
Keywords: HCV; hepatitis C virus; PI; protease inhibitor; TVR; telaprevir; Peg-IFN-α; pegylated interferon-α; RBV; ribavirin; NR; non-response; SVR; sustained virological response; NAb; neutralizing antibody; rIFN; recombinant IFN; Anti-interferon-α neutralizing
Telaprevir or boceprevir based therapy for chronic hepatitis C infection: Development of resistance-associated variants in treatment failure
Keywords: HCV; Telaprevir; Protease inhibitors; Drug resistance;
Dermatitis por telaprevir: manejo con corticoides orales en casos refractarios
Keywords: Hepatitis C; Inhibidores de la proteasa; Telaprevir; Dermatitis; Eccema; ToxicodermiaHepatitis C; Protease inhibitors; Telaprevir; Dermatitis; Eczema; Toxicoderma
Serum 25(OH)D3 levels affect treatment outcomes for telaprevir/peg-interferon/ribavirin combination therapy in genotype 1b chronic hepatitis C
Keywords: Hepatitis C virus; Pegylated interferon; Telaprevir; 25(OH)D3;
Review articleTriple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF)
Keywords: Boceprevir; Cirrhosis; Hepatitis C; Pegylated-interferon; Ribavirin; Telaprevir;
Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infection
Keywords: Hepatitis C; Telaprevir; Low-density lipoprotein cholesterol; IL28B; Pegylated interferon
Research ArticleShould we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141)
Keywords: Boceprevir; Chronic hepatitis C; Cost-effectiveness analysis; Direct-acting antivirals; Genotype 1; Interferon-free regimens; Model-based analysis; Telaprevir; Treatment initiation; G1; genotype 1; HCV; hepatitis C virus; TVR; telaprevir; BOC; boceprevir;
Research ArticleSustained virological response with telaprevir in 1078 patients with advanced hepatitis C: The international telaprevir access program
Keywords: BMI; body mass index; MELD; model for end stage liver disease; AFP; alpha-fetoprotein; BVL; baseline viral load; CI; confidence interval; Hepatitis C; Telaprevir; Cirrhosis; Pegylated interferon;
Patterns of viral load decline with telaprevir-based therapy in patients with genotype 1 chronic HCV infection
Keywords: Telaprevir; Hepatitis C; HCV RNA; Stopping rule; Viral load;
My Treatment Approach to Chronic Hepatitis CÂ Virus
Keywords: BOC; boceprevir; FDA; Food and Drug Administration; HCC; hepatocellular carcinoma; HCV; hepatitis C virus; HIV; human immunodeficiency virus; PEGINF; peginterferon; RBV; ribavirin; RVR; rapid virologic response; SMV; simeprevir; SOF; sofosbuvir; SVR; sust
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
Keywords: AE; adverse event; ALT; alanine aminotransferase; BMI; body mass index; BOC; boceprevir; BT; viral breakthrough; CPGs; Clinical Practice Guidelines; CYP3A4; cytochrome p450 3A4; DAA; direct-acting antiviral; DVR; delayed virological response; EIA; enzyme
CommentaryThe changing face of hepatitis C in the new era of direct-acting antivirals
Keywords: Hepatitis C; Direct-acting antivirals; Human immunodeficiency virus; Telaprevir; Boceprevir; Antiviral therapy;
Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced interferon resistance
Keywords: HCV; hepatitis C virus; UTR; untranslated regions; IFN; interferon; ISG; interferon stimulatory genes; IRES; internal ribosome entry site; IFNAR; IFN-α receptor; STAT; signal transducer and activator of transcription; TLR3; toll like receptor 3; DsRNA; d
Research ArticleA multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C
Keywords: CHC; chronic hepatitis C; HCC; hepatocellular carcinoma; SVR; sustained virological response; MSP; multidisciplinary support programme; pegIFN; pegylated interferon; DAA; direct-acting antivirals; TVR; telaprevir; BOC; boceprevir; RBV; ribavirin; HCV; hep
Research ArticleTelaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C
Keywords: TVR; telaprevir; RVR; rapid virological response; SVR; sustained virological response; IL28B; interleukin 28B; HCV; hepatitis C virus; HCC; hepatocellular carcinoma; PegIFN-α; pegylated interferon α; RBV; ribavirin; NS3/4A; non-structural 3/4A; DAA; dir
Research ArticleTriple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890
Keywords: Chronic hepatitis C; Cirrhosis; Treatment; Boceprevir; Telaprevir; Safety; HCV; hepatitis C virus; ANRS; agence nationale de recherches sur le SIDA et les hépatites virales; AFEF; Association Française pour l'Etude du Foie; PegIFN; pegylated interfero
Research ArticleClinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy
Keywords: HCV; hepatitis C virus; PegIFN; pegylated interferon; RBV; ribavirin; SVR; sustained virological response; TVR; telaprevir; ITPA; inosine triphosphatase; SNP; single nucleotide polymorphism; Hb; hemoglobin; eGFR; estimated glomerular filtration rate; RVR;
Research ArticleCost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C
Keywords: CHC; chronic hepatitis C; G1; genotype 1; DT; dual therapy; PegIFN; pegylated interferon; RBV; ribavirin; PI; protease inhibitors; BOC; boceprevir; TVR; telaprevir; ICER; incremental cost-effectiveness ratio; NR; non-response; PAR; partial response; RR; r
A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir
Keywords: UPLC-MS/MS; Plasma; HCV; Telaprevir; Boceprevir;
Optimizing DAA management in daily practice
Keywords: Adherence; Anaemia; Boceprevir; Drug–drug interaction; Educational nurse; Skin rash; Stopping rules; Telaprevir; Triple therapy
Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response
Keywords: Hepatitis C; HIV; Pegylated interferon; Ribavirin; Boceprevir; Telaprevir; IL28B; Rapid virological response
Avances en el tratamiento de la hepatitis C
Keywords: Hepatitis C; Inhibidores de la proteasa; Boceprevir; Telaprevir; Interferón pegilado; RibavirinaHepatitis C; Protease inhibitors; Boceprevir; Telaprevir; Pegylated interferon; Ribavirine
Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: A comparison of two real-time PCR assays
Keywords: Hepatitis C; Telaprevir; RealTime PCR assay; Pegylated interferon; Ribavirin
Directly acting antivirals for the treatment of chronic hepatitis C: Unresolved topics from registration trials
Keywords: Boceprevir; Cirrhosis; Guidelines; HCV; IL28B; Lead-in; Telaprevir
Telaprevir Versus Boceprevir in Chronic Hepatitis C: A Meta-Analysis of Data From Phase II and III Trials
Keywords: boceprevir; chronic hepatitis C; hepatitis C genotype 1; protease inhibitors; telaprevir
Emerging Therapeutic Targets for Hepatitis C Virus Infection
Keywords: Hepatitis C; Direct Acting Antivirals; Interferon-free Therapy; Telaprevir; Boceprevir; DAA; direct acting antiviral; HCV; hepatitis C virus; IL; interleukin; NS; nonstructural; Peg-IFN; pegylated interferon; quad; quadruple; RBV; ribavirin; RGT; response
Validation of an electrospray ionisation LC–MS/MS method for quantitative analysis of telaprevir and its R-diastereomer
Keywords: Hepatitis C; Telaprevir; VRT-127394; LC–MS/MS; Method validation; Ex vivo interconversion
Interacciones farmacocinéticas de telaprevir con otros fármacos
Keywords: Telaprevir; Interacción farmacocinética; Hepatitis C; Antirretrovirales; Virus de la inmunodeficiencia humana; VIHTelaprevir; Pharmacokinetic interactions; Hepatitis C; Antiretroviral drugs; Human immunodeficiency virus; HIV